Cerenome picks XiFin for billing services on CNSide platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
August 6, 2026 7:30 AM EDTHOUSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (Cerenome or the Company), announced today that it has selected XiFin, Inc. (XiFin), a market leader in artificial intelligence (AI)-driven revenue cycle management (RCM) for diagnostic providers, to provide billing and clearinghouse services for the CNSide® Cerebrospinal Fluid (CSF) Assay Platform. The Company expects to commence billing through the XiFin platform during the third quarter of 2026, including submission of the accumulated backlog of previously performed CNSide® tests.
XiFin Empower RCM provides end-to-end revenue cycle infrastructure purpose-built for... More
